1 / 63

ONDERSTEPOORT BIOLOGICAL PRODUCTS LTD

ONDERSTEPOORT BIOLOGICAL PRODUCTS LTD. PRESENTATION TO THE PORTFOLIO COMMITTEE: 8 MARCH 2006. PRESENTATION OUTLINE:. Introduction (Ms N D Shabalala, Board Chairperson) Business Plan (Dr L Makuleni – Managing Director)

aideen
Télécharger la présentation

ONDERSTEPOORT BIOLOGICAL PRODUCTS LTD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. ONDERSTEPOORT BIOLOGICAL PRODUCTS LTD PRESENTATION TO THE PORTFOLIO COMMITTEE: 8 MARCH 2006

  2. PRESENTATION OUTLINE: • Introduction (Ms N D Shabalala, Board Chairperson) • Business Plan (Dr L Makuleni – Managing Director) • Budget 2006/07 (Mr M P van Jaarsveld – Chief Financial Officer) • Conclusion (Dr L Makuleni)

  3. INTRODUCTION

  4. OBP FUNCTIONING BOARD COMMITTEES

  5. FUNCTIONING OF BOARD COMMITTEES • Remuneration Committee: • Remuneration: • Directors • Executives • Employees • Assessment of Performance • Human Resource Matters

  6. FUNCTIONING OF BOARD COMMITTEES • Audit Committee: • Controls: • Internal Audit • External Audit • Financial Matters • Management Accounts • Investments • Financial Policies

  7. FUNCTIONING OF BOARD COMMITTEES • Risk Management Committee: • Annual Risk Assessment • Risk Management – mitigating risks

  8. FUNCTIONING OF BOARD COMMITTEES • Research and Development Committee: • Monitor and assess R & D projects • Intellectual Property Management

  9. BUSINESS PLAN 2006/07:

  10. Business Plan • OBP Mandate • Market Definition • Situation Analysis • Primary Strategic Objectives • Primary Strategic Initiatives

  11. COMPANY MANDATE “To play a pivotal role in the management and prevention of animal diseases in the Country, SADC, and Africa”

  12. MARKET DEFINITION : • Biotechnology, Animal Health, Veterinary Vaccines • Geographic Focus • Domestic • Commercial • Emerging sector • Government Tender Business • International: • SADC, East Africa, North Africa, West Africa • EU • Middle East • South America • India, China

  13. MARKET DEFINITION : • Target Species: • Cattle, Sheep, Goats, Horses • Other possible species (e.g. poultry, rabies, camel) • 50 Products: • Bacterial, Viral, protozoa and diagnostic • Produce vaccines unique to African disease (tick- borne and insect-borne, African Horse Sickness, Bluetongue, Lumpy Skin Disease, Rift valley Fever, CBPP) • Sole / main producer of eight vaccines • Broad product range (Clostridial, Neo-natal, reproductive, respiratory etc.) • Local Strains

  14. MARKET DEFINITION: SOUTH AFRICAN ANIMAL HEALTH MARKET SIZEFOR THE 2005 CALENDAR YEAR • Total Market R843 million • Antibiotics R241 million • Ectos R161 million • Endectos R76 million • Endos R65 million • Vet. Vaccines R70 million (excluding Intervet) (OBP Ltd R 38.8 million)

  15. SITUATION ANALYSIS: • Well established competitors • Well trained sales, marketing, and technical staff • Broader Animal Health Product Range • Distribution channels established and profit margin driven • Stringent Regulatory requirement Internationally, Local Regulatory requirement less stringent • International Markets Requirement - GMP Accreditation • Well informed customers • Outbreaks of Trans-Boundary Diseases

  16. STRATEGIC OBJECTIVES : • Financial objectives • Sales Revenue • 2006/07 = R113.65m • 2007/08 = R136.48m • 2008/09 = R164.18m • Obtain gross profit margin of 35%

  17. STRATEGIC OBJECTIVES: 2005/6 • Financial • Capex spend of R33 million • R&D operational expenses 5% of Sales Revenue • BEE: 40% x Procurement

  18. STRATEGIC OBJECTIVES 2005/6 • Non – Financial • Upgrade of Packaging Department • Production Success Rate 90% • ISO Accreditation Audit Review • Release 2 products per year • EE & Skills Plan • Implement Succession Plan • Ensure Good Corporate Governance: • Risk Assessment • Three year rolling Internal Audit Plan

  19. STRATEGIC OBJECTIVES HRD BUDGET 2005/06

  20. STRATEGIC OBJECTIVES HRD BUDGET 2006/7

  21. EMPLOYMENT EQUITY TARGETS 2005/6

  22. EMPLOYMENT EQUITY ACTUAL TO DATE

  23. EMPLOYMENT EQUITY ACTUAL VS. TARGET FOR 2006/7

  24. EMPLOYMENT EQUITY TARGET STATS 2006/7

  25. EMPLOYMENT EQUITY TARGET 2006/7

  26. GENDER ACTUAL VS TARGET 2006/7

  27. GENDER ACTUAL VS TARGET 2006/7

  28. STRATEGIC INITIATIVES 2005/6 • OBP Strategic Initiatives - - National Imperatives • Investment in Infrastructure • Skills Development • Accelerated Growth: Livestock Sector

  29. OBP Strategic Initiatives 2005/6 • OBP Strategic Initiatives - - National Imperatives • Investment in Infrastructure • Upgrade of Facility and Equipment - GMP • Improve Production Processes • Improve Production Planning System • Preventative Maintenance of Facility and Equipment

  30. OBP Strategic Initiatives 2005/6 • OBP Strategic Initiatives - - National Imperatives: • Skills Development • OBP Technical , Sales & Marketing Dept • Farmers days ( NB OBP, Provincial Dept – AHT & State vets,) • Disease management program • OBP/ UP /ARC-OVI : Collaboration • Expert Panel Meetings

  31. OBP Strategic Initiatives 2005/6 • OBP Strategic Initiatives - - National Imperatives: • Build Expertise • Production Process Technology • IP management • Learnership Program - Process Engineers in Biotechnology • Building R&D capacity & capability • Succession Planning

  32. OBP Strategic Initiatives 2005/6 • OBP Strategic Initiatives - - National Imperatives • Accelerated Growth: • Marketing and Distribution • Vaccine manufacturing facilities within the Continent • R&D on Trans boundary diseases – vaccines • CBPP, Rinderpest, PPR, Sheep & Goat Pox

  33. OBP Strategic Initiatives 2005/6 • OBP Strategic Initiatives - - National Imperatives • Accelerated Growth: • New / Improved Products • Master Seed Management • Total Quality Management • Experimental Animal Facility • International Registration of OBP Product Line

  34. BUDGET: 2006/07

  35. PROFIT BEFORE INTEREST & TAX

  36. PROFIT BEFORE INTEREST & TAX R8.9m Improvement due to: • Increase in Sales 22% In spite of • Increase in Cost of Sales (-10%) • Increase in Overheads (-15%)

  37. INCREASE IN SALES

  38. COST OF SALES

  39. COST OF SALES R6.0m Increase due to: • Increased repair & maintenance R1m • Increased Depreciation R5m

  40. OVERHEAD EXPENSES

  41. OVERHEAD EXPENSES R5.5m Increase due to: • New positions & vacancies R3.7m • Market related salary adjustment R3.1m • Contractors (Work study, Audits, etc.) R0.6m • Increased Travel: R0.8m

  42. OVERHEAD EXPENSES R5.5m Increase due to: • Increased Marketing: R0.9m • Other R0.4m • Higher salary recovery in COS (-R4.0m)

  43. CASH FLOW 2006/07

  44. CAPITAL EXPENDITURE

  45. GRAPHICAL COMPARISON OF BUDGET TO PREVIOUS YEARS • Sales (Local & Export) • Expenses • Expenses as % of sales

More Related